Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DVC1 0101

Drug Profile

DVC1 0101

Alternative Names: Angiogenic-gene-therapy-ID-Pharma; BF-30; DVC1-0101; Fibroblast growth factor 2 gene therapy - ID Pharma; Recombinant SeV-hFGF2/dF; SeV-10101; SeV-hFGF2/dF; SEV1-0101

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DNAVEC Corporation
  • Developer ID Pharma; Kyushu University; Shenzhen Salubris Pharmaceuticals
  • Class Anti-ischaemics; Gene therapies; Nucleic acids; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intermittent claudication; Peripheral ischaemia
  • Phase I Peripheral arterial occlusive disorders

Most Recent Events

  • 05 Sep 2018 Phase-I clinical trials in Peripheral arterial occlusive disorders in China (IM) (NCT03668353)
  • 22 Nov 2016 Phase-I/II clinical trials in Intermittent claudication in Australia (IM) (ACTRN12615001144505)
  • 22 Nov 2016 Phase-I/II clinical trials in Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top